Loading
Seattle oncologist who led STAMP, the trial that showed pembrolizumab after surgery reduces recurrence of Merkel cell carcinoma, a rare and aggressive skin cancer.
Shailender Bhatia is a medical oncologist at Fred Hutchinson Cancer Center and the University of Washington who focuses on Merkel cell carcinoma and melanoma. He was the study chair and first author of the 2025 New England Journal of Medicine report of the ECOG-ACRIN EA6174 STAMP trial, in which adjuvant pembrolizumab improved recurrence-free survival compared with observation after resection of stage I to III Merkel cell carcinoma.
| Title | Journal | Year |
|---|---|---|
| Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab Europe PMC author record matched by affiliation (Fred Hutchinson Cancer Center); 1984 citations on Europe PMC. | Cell | 2017 |
| CheckMate 238: adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma Europe PMC author record matched by affiliation (Fred Hutchinson Cancer Center); 1713 citations on Europe PMC. | New England Journal of Medicine | 2017 |
| PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma Europe PMC author record matched by affiliation (Fred Hutchinson Cancer Center); 950 citations on Europe PMC. | New England Journal of Medicine | 2016 |
One of the most cited papers Europe PMC returns for Shailender Bhatia at Fred Hutchinson Cancer Center, so it is a natural starting point for reading their work. The record was linked automatically from the author list and affiliation; read the abstract above and the paper itself before relying on any figure.
Adjuvant nivolumab (or pembrolizumab) is standard for resected stage III and IV melanoma; ipilimumab is no longer used in the adjuvant setting.
This is the paper Europe PMC returns for registry id NCT02267603 with the most citations, so it is the natural first reading for anyone following the KEYNOTE-017 trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
Shares Skin cancer (all types) and the tags skin, immunotherapy, trialist.
Shares Skin cancer (all types), Melanoma and the tags skin, immunotherapy, trialist.
Shares Skin cancer (all types) and the tags skin, immunotherapy, trialist.
Shares Skin cancer (all types) and the tags skin, immunotherapy, trialist.
Shares Melanoma and the tags immunotherapy, trialist.
Shares Skin cancer (all types) and the tags skin, trialist.
Shares Skin cancer (all types) and the tags skin, immunotherapy.
Shares Melanoma and the tags immunotherapy, trialist.